Envestnet Portfolio Solutions Inc. Purchases 7,465 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Envestnet Portfolio Solutions Inc. increased its stake in Jazz Pharmaceuticals PLC by 170.9% in Q2, acquiring an additional 7,465 shares, bringing its total holdings to 11,834 shares valued at approximately $1.26 million.
• Several hedge funds, including Philip James Wealth Management LLC and State of Alaska Department of Revenue, significantly increased their positions in Jazz Pharmaceuticals, indicating strong institutional interest in the stock.
• Wall Street analysts have positive outlooks for Jazz Pharmaceuticals, with target price increases by institutions like Royal Bank Of Canada and Truist Financial, reflecting projected growth and a consensus rating of "Moderate Buy."

Envestnet Portfolio Solutions Inc. grew its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 170.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,834 shares of the specialty pharmaceutical company's stock after acquiring an additional 7,465 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Jazz Pharmaceuticals were worth $1,256,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of JAZZ. Philip James Wealth Mangement LLC lifted its position in shares of Jazz Pharmaceuticals by 42.0% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company's stock worth $1,676,000 after buying an additional 4,675 shares during the period. State of Alaska Department of Revenue lifted its position in shares of Jazz Pharmaceuticals by 75.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company's stock worth $6,147,000 after buying an additional 24,850 shares during the period. Inspire Investing LLC bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $689,000. Baird Financial Group Inc. bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $539,000. Finally, Voya Investment Management LLC lifted its position in shares of Jazz Pharmaceuticals by 67.1% during the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company's stock worth $6,996,000 after buying an additional 22,628 shares during the period. Institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several analyst reports. Royal Bank Of Canada raised their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Truist Financial raised their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a research report on Thursday, August 28th. Needham & Company LLC restated a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Finally, Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an "overweight" rating in a research report on Wednesday, September 24th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $178.93.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the completion of the sale, the director directly owned 408,826 shares of the company's stock, valued at approximately $57,235,640. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Trading Up 1.3%

Shares of JAZZ opened at $136.06 on Friday. The stock has a fifty day moving average price of $128.20 and a two-hundred day moving average price of $116.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a market cap of $8.25 billion, a price-to-earnings ratio of -20.22, a PEG ratio of 8.35 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm's quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the business posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.